Form 144 notice for Eli Lilly & Co. (LLY) reports a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on 08/28/2025 on the NYSE with an aggregate market value of $1,468,340.00. The shares were acquired as Restricted Stock Units on 02/09/2022 from the issuer and payment information is listed as N/A.
The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of undisclosed material adverse information and provides space for signature and plan-adoption dates, but those fields are not populated in the supplied content.
Kenneth L. Custer, EVP & President, Card Met Hlth at Eli Lilly & Co (LLY), reported insider transactions dated 08/27/2025 and filed 08/28/2025. The filing shows a disposition of 9,346.902 shares of Eli Lilly common stock. It also reports a reallocation within the reporting person's deferred compensation account resulting in 612.937 shares of phantom stock (payable in cash after employment termination). After the reported transactions, the filing states the reporting person beneficially owns 2,173.461 shares of common stock. The form is signed on behalf of Mr. Custer by an authorized representative.
Donald A. Zakrowski, Senior Vice President, Finance & Chief Accounting Officer at Eli Lilly & Co. (LLY), reported a sale of 1,000 shares of Eli Lilly common stock on 08/28/2025 at a price of $734.93 per share. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the transaction, the reporting person beneficially owned 3,839.659 shares directly and 1,725.72 shares indirectly (401(k)). The Form 4 was signed by an authorized representative on behalf of Mr. Zakrowski.
Eli Lilly & Company filed an 8-K disclosing documentation related to a debt offering. The filing includes an Underwriting Agreement dated August 18, 2025, an Indenture (originally dated February 1, 1991) and a Tripartite Agreement appointing Deutsche Bank Trust Company Americas as successor trustee. The exhibits provide forms of Fixed Rate and Floating Rate Notes, including a Floating Rate Note due 2028 and fixed-rate notes with stated coupons of 4.000% (2028), 4.250% (2031), 4.550% (2032), 4.900% (2035), 5.550% (2055) and 5.650% (2065). Legal opinions by Kirkland & Ellis LLP and Jamie Burnett, Esq., and their consents are included, as well as a Cover Page Interactive Data File. The filing is signed by Jon Haug, Senior Vice President, Treasurer and Corporate Finance and Investment Banking, dated August 20, 2025.
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported an acquisition of 2,710.158 shares of common stock on 08/18/2025. The filing shows the shares were acquired at a price of $698.05 and, at the reporting person’s election, have been deferred as stock units under the Lilly Directors' Deferral Plan. Those units will be settled in shares of common stock following the reporting person’s separation from service. The Form 4 was signed and submitted on 08/19/2025.
Juan R. Luciano, a director of Eli Lilly & Co. (LLY), reported an acquisition on 08/18/2025 recorded on a Form 4. The filing shows a Code V transaction (shares acquired pursuant to a plan) and lists 16,403.184 as the amount of securities beneficially owned following the reported transaction. The filing also references $698.05 and includes an explanatory note that the shares acquired were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported a transaction on 08/18/2025 in which shares were acquired under the companys director deferral arrangements. The filing shows an acquisition (Code A) of 14.206 units at a reported price of $698.05. The report lists 1,986.78 shares beneficially owned following the transaction, with ownership reported as direct and indirect (by trust) where applicable. The filing explains the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors Deferral Plan and will be settled in common stock after the reporting persons separation from service. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported acquiring 74,591.985 shares of the company's common stock on 08/18/2025 at a per-share price of $698.05. The filing states these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares following the reporting person’s separation from service. The transaction is reported as an acquisition of non-derivative common stock via Code A (acquisition).
Ralph Alvarez, a director of Eli Lilly & Co. (LLY), reported a non-derivative acquisition on 08/18/2025. The filing shows an acquisition entry with notation "16.833(1) A $698.05 55,011.413 D" and indicates 758 shares are held indirectly by trust. The reporting person elected to defer the acquired shares as stock units under the Lilly Directors' Deferral Plan; those units will be settled in common stock following his separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form was signed on 08/19/2025.
Eli Lilly executive Lucas E. Montarce reported an open-market purchase of 715 shares of Eli Lilly common stock at a weighted-average price of $691.786, executed in multiple trades at prices between $691.67 and $691.90. After the reported purchases, the reporting person beneficially owns 14,684.736 shares of the company's common stock. The filing identifies the reporting person as an officer (EVP & CFO) and includes an undertaking to provide details of the number of shares bought at each separate price within the stated range upon request.